Background: Immune thrombocytopenia (ITP) is characterized by immune-mediated platelet destruction and impaired megakaryocyte maturation. Hypoxia-inducible factor-1 alpha (HIF-1α), pivotal in the development of megakaryocytes and immune regulation, is downregulated in ITP, suggesting its role in disease pathogenesis. Given this relationship, roxadustat as an HIF-1α stabilizer, is a potential therapeutic agent in the treatment of ITP by augmenting HIF-1α mediated megakaryocyte development and immune system modulation.
Objectives: This study evaluates the safety profile of roxadustat and its therapeutic efficacy for ITP treatment using Mendelian randomization (MR) analysis.
Methods: We used expression Quantitative Trait Loci (eQTLseQTLs) data for roxadustat's target genes (EGLN1, EGLN2, EGLN3) and genetic associations with ITP, and adverse outcomes from the IEU OpenGWAS project. MR analysis included IVW, MR-Egger regression, weighted median, and MR-PRESSO methods to evaluate pleiotropy. Heterogeneity was assessed using Cochran's Q statistic and I² measure, with sensitivity analyses. A meta-analysis was performed to integrate effect sizes from multiple literature sources.
Results: MR analysis revealed a significant association between roxadustat and reduced ITP risk (OR 0.79, 95% CI 0.66-0.95, P=0.01) with no evidence of horizontal pleiotropy. Meta-analysis confirmed the protective effect of roxadustat on ITP risk. Utilizing eQTLs of roxadustat's target gene EGLN1 as instrumental variables, an MR analysis of 39 potential adverse reactions revealed no significant increase in risk, indicating a favorable safety profile for roxadustat.
Conclusion: Roxadustat demonstrates a potential protective effect against ITP without increasing the risk of adverse outcomes, suggesting its promise as a therapeutic option for ITP and warranting further investigation.
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal